The TNFSF11 (Denosu) Biosimilar (HDBS0057) is a highly specialized biologic medication designed to target and inhibit the activity of TNFSF11, a key regulatory molecule in bone metabolism and immune system modulation. This biosimilar drug is produced using advanced biotechnological processes to mimic the therapeutic effects of the original medication, providing a cost-effective alternative for patients in need of TNFSF11 inhibition therapy.TNFSF11, also known as RANKL, plays a crucial role in the regulation of bone remodeling and immune cell differentiation. By targeting TNFSF11 with the Denosu biosimilar, healthcare providers can effectively manage conditions such as osteoporosis, bone metastasis, and autoimmune diseases that are driven by excessive TNFSF11 activity.
This biosimilar medication offers a safe and reliable option for patients requiring TNFSF11 inhibition therapy, with proven efficacy and tolerability in clinical trials. With its targeted mechanism of action and bioequivalence to the original medication, the TNFSF11 (Denosu) Biosimilar (HDBS0057) is a valuable addition to the treatment armamentarium for bone-related disorders and immune-mediated conditions.
Product Name:
Denosumab (Anti-TNFSF11) Biosimilar Antibody
Size:
100 ug
Product SKU:
HDBS0057
Target:
TNFSF11
Host Species:
Homo sapiens
Reactivity:
Human
Recommended Dilution:
Flow Cyt 1:100
Antibody Type:
Monoclonal
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
AMG162
Description:
Anti-TNFSF11 (denosumab biosimilar)mAb
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
Flow Cyt
Antibody Isotype:
IgG2
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
